These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 23061678)

  • 1. Gemcitabine, oxaliplatin and dexamethasone as salvage treatment for elderly patients with refractory and relapsed peripheral T-cell lymphoma.
    Yao YY; Tang Y; Zhu Q; Zhuang Y; Cheng YM; Wang L; Zou LF
    Leuk Lymphoma; 2013 Jun; 54(6):1194-200. PubMed ID: 23061678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study.
    Corazzelli G; Russo F; Capobianco G; Marcacci G; Della Cioppa P; Pinto A
    Ann Oncol; 2006 May; 17 Suppl 4():iv18-24. PubMed ID: 16702180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial.
    Park BB; Kim WS; Suh C; Shin DY; Kim JA; Kim HG; Lee WS
    Ann Hematol; 2015 Nov; 94(11):1845-51. PubMed ID: 26251158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine, dexamethasone, and cisplatin (GDP) as salvage chemotherapy for patients with relapsed or refractory peripheral T cell lymphoma-not otherwise specified.
    Qi F; Dong M; He X; Li Y; Wang W; Liu P; Yang J; Gui L; Zhang C; Yang S; Zhou S; Shi Y
    Ann Hematol; 2017 Feb; 96(2):245-251. PubMed ID: 27858107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biweekly dose-dense gemcitabine-oxaliplatin and dexamethasone for relapsed/refractory aggressive non-Hodgkin lymphoma: A multicenter, single-arm, phase II trial.
    Jo JC; Baek JH; Lee JH; Joo YD; Bae SH; Lee JL; Lee JH; Kim DY; Lee WS; Ryoo HM; Choi Y; Kim H; Lee KH;
    Asia Pac J Clin Oncol; 2016 Jun; 12(2):159-66. PubMed ID: 26956432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salvage therapy with gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for B-cell non-Hodgkin's lymphoma: a consortium for improving survival of lymphoma (CISL) trial.
    Park BB; Kim WS; Eom HS; Kim JS; Lee YY; Oh SJ; Lee DH; Suh C
    Invest New Drugs; 2011 Feb; 29(1):154-60. PubMed ID: 19756371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma.
    Corazzelli G; Capobianco G; Arcamone M; Ballerini PF; Iannitto E; Russo F; Frigeri F; Becchimanzi C; Marcacci G; De Chiara A; Pinto A
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):907-16. PubMed ID: 19219604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sintilimab plus GemOx is an effective salvage therapy in patients with refractory/relapsing nodal peripheral T cell lymphomas.
    Xiao X; Hu M; Jiang H; Chen P; Lei H
    J Cancer Res Clin Oncol; 2024 Sep; 150(9):425. PubMed ID: 39299973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II Trial Using Romidepsin after Gemcitabine, Dexamethasone, and Cisplatin Therapy in Elderly Transplant-Ineligible Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma: Study Protocol.
    Yamasaki S; Kada A; Nagai H; Yoshida I; Choi I; Saito AM; Iwasaki H
    Acta Med Okayama; 2019 Oct; 73(5):469-474. PubMed ID: 31649375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy.
    El Gnaoui T; Dupuis J; Belhadj K; Jais JP; Rahmouni A; Copie-Bergman C; Gaillard I; Diviné M; Tabah-Fisch I; Reyes F; Haioun C
    Ann Oncol; 2007 Aug; 18(8):1363-8. PubMed ID: 17496309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxaliplatin-based chemotherapy (dexamethasone, high-dose cytarabine, and oxaliplatin)±rituximab is an effective salvage regimen in patients with relapsed or refractory lymphoma.
    Rigacci L; Fabbri A; Puccini B; Chitarrelli I; Chiappella A; Vitolo U; Levis A; Lauria F; Bosi A
    Cancer; 2010 Oct; 116(19):4573-9. PubMed ID: 20572029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas.
    Evens AM; Rosen ST; Helenowski I; Kline J; Larsen A; Colvin J; Winter JN; van Besien KM; Gordon LI; Smith SM
    Br J Haematol; 2013 Oct; 163(1):55-61. PubMed ID: 23927371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients.
    Pellegrini C; Dodero A; Chiappella A; Monaco F; Degl'Innocenti D; Salvi F; Vitolo U; Argnani L; Corradini P; Zinzani PL;
    J Hematol Oncol; 2016 Apr; 9():38. PubMed ID: 27071522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A New Salvage Regimen for Aggressive Lymphomas Based on Gemcitabine, Rituximab, and Oxaliplatin Followed by Lenalidomide (GROC-Rev).
    Cabanillas F; Rivera N; Acosta M; Pardo W; Solivan P; Rivera C; Liboy I
    Clin Lymphoma Myeloma Leuk; 2019 Dec; 19(12):776-783. PubMed ID: 31591042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine, cisplatin, and dexamethasone (GDP) in combination with methotrexate and pegaspargase is active in newly diagnosed peripheral T cell lymphoma patients: a phase 2, single-center, open-label study in China.
    Zhang Y; Zhang W; Li J; Duan M; Han B; Zhu T; Zhuang J; Cai H; Cao X; Chen M; Zhou D
    Ann Hematol; 2019 Jan; 98(1):143-150. PubMed ID: 30209556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group.
    Kollmannsberger C; Beyer J; Liersch R; Schoeffski P; Metzner B; Hartmann JT; Rick O; Stengele K; Hohloch K; Spott C; Kanz L; Bokemeyer C
    J Clin Oncol; 2004 Jan; 22(1):108-14. PubMed ID: 14701772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome for patients with relapsed/refractory aggressive lymphoma treated with gemcitabine and oxaliplatin with or without rituximab; a retrospective, multicentre study.
    Dhanapal V; Gunasekara M; Lianwea C; Marcus R; De Lord C; Bowcock S; Devereux S; Patten P; Yallop D; Wrench D; Fields P; Kassam S
    Leuk Lymphoma; 2017 Sep; 58(9):1-9. PubMed ID: 28093003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy of GDP regimen (gemcitabine, dexamethasone, and cisplatin) on relapsed or refractory aggressive non-Hodgkin's Lymphoma: a report of 24 cases].
    Fan Y; Huang ZY; Luo LH; Yu HF
    Ai Zheng; 2008 Nov; 27(11):1222-5. PubMed ID: 19000458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral T-cell lymphoma: analysis of efficacy and toxicity.
    Kim SJ; Kim K; Park Y; Kim BS; Huh J; Ko YH; Park K; Suh C; Kim WS
    Invest New Drugs; 2012 Feb; 30(1):368-75. PubMed ID: 20734108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine, vinorelbine and dexamethasone: A safe and effective regimen for treatment of relapsed/refractory hodgkin's lymphoma.
    Ganesan P; Mehra N; Joel A; Radhakrishnan V; Dhanushkodi M; Perumal Kalayarasi J; Kannan K; Ganesan TS; Sagar TG
    Leuk Res; 2019 Sep; 84():106188. PubMed ID: 31325732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.